|Day Low/High||34.21 / 35.23|
|52 Wk Low/High||33.61 / 76.81|
The Dow, Nasdaq and S&P were all in the red Tuesday.
-- Infantile hyperbilirubinemia (jaundice) affects approximately 750,000 infants born in the U.S. each year; if unresolved with traditional treatment, can lead to serious medical conditions including permanent neurological injury and death --
-- Observational Registry With Retrospective Data Collection Designed to Evaluate Premature Versus Term and Near-Term Neonates with Pulmonary Hypertension Receiving Inhaled Nitric Oxide --
-- Literature review covering decades of data support combination of clinical outcomes, lower use of background medications and reduced post-therapy costs --
McCaskill requested that four more drug companies and three drug distributors turn over documents.
Distortions caused by all these earnings reports coming at once are causing upheaval in the market.
Jim Cramer is bullish on Marriott International, Ionis Pharmaceuticals, and NXP Semiconductors.
-- Terlipressin CONFIRM Phase 3 Trial Enrolls 75th Patient of 300-Patient Target Enrollment; Marks Halfway Point toward Interim Analysis of Trial Data --
-- Mallinckrodt Reaffirms Industry-Leading Commitment to Ensuring Safe and Appropriate Use of its Specialty Generic Opioid Products --
-- R&D-Focused Event to Highlight Commercial Portfolio and Growing Pipeline --
-- Long Hospital Stays, Frequent Medical Visits and Hospital Readmissions Drive Costs, Payer Burden --
Individual state investigations of opioid marketing practices has lead to a multistate investigation of the prescription painkiller industry.
--Mallinckrodt's PENNANT Trial to Assess Efficacy and Safety of H.P. Acthar Gel in ALS Patients--
-- Trial to Assess Efficacy and Safety in the Promotion of Autologous Skin Regeneration of Complex Skin Defects Due to Thermal Burns That Contain Intact Dermal Elements --
Wall Street wasn't able to extend a record-breaking streak into a third session on Monday after a terror attack in London.
Wall Street couldn't extend a record-breaking steak into a third session following the weekend terror attack in London.
Stocks are mostly lower on Monday after a terror attack in London over the weekend and following a rare analyst downgrade on Apple shares.
Citron attacked Mallinckrodt's partnership with Express Scripts ESRX, liking it to the role specialty prescription company Philidor played for embattled pharma company Valeant.
Shares of drug maker Mallinckrodt were falling Wednesday afternoon
The unit accounted for about 30% of the company's revenue in the first quarter.
More competition could help overcome the suspicion over drug prices that plagues the would-be business partners' dealings.
-- Preliminary Demographic Data on Currently Enrolled Patients to be Presented at the 2017 Annual Meeting of the Consortium of Multiple Sclerosis Centers [Poster RT01] --
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.